BECOME A MEMBER
Connect with healthcare professionals around the globe to get the most up-to-date medical cannabis information.
Get Involved
TAKE OUR COURSES
The curriculum brings hands-on practical guidance on how to develop personalized treatment regimens and more.
Cannabinoid exposure in adolescent female rats induces transgenerational effects on morphine conditioned place preference in male offspring.
Authors: John J Byrnes, Nicole L Johnson, Marian E Schenk, Elizabeth M Byrnes
Journal of Psychopharmacology, October 2012
—
In the United States, marijuana is one of the drugs most abused by adolescents, with females representing a growing number of users. In previous studies, treatment of adolescent female rats with morphine significantly altered brain reward systems in future offspring. As both c…
Mitigation of post-traumatic stress symptoms by Cannabis resin: a review of the clinical and neurobiological evidence.
Authors: Torsten Passie, Hinderk M. Emrich, Matthias Karst, Simon D. Brandt, John H. Halpern
Drug Testing and Analysis, July-August 2012
—
It is known from clinical studies that some patients attempt to cope with the symptoms of post-traumatic stress disorder (PTSD) by using recreational drugs. This review presents a case report of a 19-year-old male patient with a spectrum of severe PTSD symptoms, such as intens…
Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial.
Authors: Jody Corey-Bloom, Tanya Wolfson, Anthony Gamst, Shelia Jin, Thomas D. Marcotte, et al
CMAJ, 10 July 2012
—
BACKGROUND: Spasticity is a common and poorly controlled symptom of multiple sclerosis. Our objective was to determine the short-term effect of smoked cannabis on this symptom. METHODS: We conducted a placebo-controlled, crossover trial involving adult patients with multiple s…
Cannabinoid receptor type 1 and 2 expression in the skin of healthy dogs and dogs with atopic dermatitis.
Authors: Luca Campora, Vincenzo Miragliotta, Emanuele Ricci, Luigia Cristino, Vincenzo Di Marzo, et al
American Journal of Veterinary Research, July 2012
—
OBJECTIVE: To determine the distribution of cannabinoid receptor type 1 (CB1) and cannabinoid receptor type 2 (CB2) in skin (including hair follicles and sweat and sebaceous glands) of clinically normal dogs and dogs with atopic dermatitis (AD) and to compare results with thos…
Circulating endocannabinoid concentrations and sexual arousal in women.
Authors: Carolin Klein, Matthew N. Hill, Sabrina C.H. Chang, Cecilia J. Hillard, Boris B. Gorzalka
Journal of Sexual Medicine, June 2012
—
INTRODUCTION: Several lines of evidence point to the potential role of the endocannabinoid system in female sexual functioning. These include results from studies describing the subjective effects of exogenous cannabinoids on sexual functioning in humans and the observable eff…
Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.
Authors: Alexandre Rafael de Mello Schier, Natalia Pinho de Oliveira Ribeiro, et al
Brazilian Journal of Psychiatry, June 2012
—
OBJECTIVES: To review and describe studies of the non-psychotomimetic constituent of Cannabis sativa, cannabidiol (CBD), as an anxiolytic drug and discuss its possible mechanisms of action. METHOD:
The articles selected for the review were identified through searches in Englis…
Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial.
Authors: Russell K. Portenoy, Elena Doina Ganae-Motan, Silvia Allende, Ronald Yanagihara, et al
The Journal of Pain, May 2012
—
Patients with advanced cancer who have pain that responds poorly to opioid therapy pose a clinical challenge. Nabiximols (Nabiximols is the U.S. Adopted Name [USAN] for Sativex [GW Pharma Ltd, Wiltshire, U.K.], which does not yet have an INN), a novel cannabinoid formulation, …
Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial.
Authors: Russell K. Portenoy, Elena Doina Ganae-Motan, Silvia Allende, Ronald Yanagihara, et al
The Journal of Pain, May 2012
—
Patients with advanced cancer who have pain that responds poorly to opioid therapy pose a clinical challenge. Nabiximols (Nabiximols is the U.S. Adopted Name [USAN] for Sativex [GW Pharma Ltd, Wiltshire, U.K.], which does not yet have an INN), a novel cannabinoid formulation…
Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1.
Authors: Robert Ramer, Katharina Bublitz, Nadine Freimuth, Jutta Merkord, Helga Rohde, et al
The FASEB Journal, April 2012
—
Cannabinoids inhibit cancer cell invasion via increasing tissue inhibitor of matrix metalloproteinases-1 (TIMP-1). This study investigates the role of intercellular adhesion molecule-1 (ICAM-1) within this action. In the lung cancer cell lines A549, H358, and H460, cannabidiol…
Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives.
Authors: Simone Tambaro, Marco Bortolato
Recent Patents on CNS Drug Discovery, 1 April 2012
—
Rich evidence has shown that cannabis products exert a broad gamut of effects on emotional regulation. The main psychoactive ingredient of hemp, Δ9-tetrahydrocannabinol (THC), and its synthetic cannabinoid analogs have been reported to either attenuate or exacerbate anxiety an…
Would some cannabinoids ameliorate symptoms of autism?
Authors: Rami Bou Khalil
European Child & Adolescent Psychiatry, DATE
—
Dear Sir, There has been a massive growth of public awareness and research funding around autism spectrum disorders (ASD) over the past 10 years. This disorder is one of the groups of neurodevelopmental disorders known as pervasive developmental disorders characterized by thre…
Cannabinoid receptor 2-mediated attenuation of CXCR4-tropic HIV infection in primary CD4+ T cells.
Authors: Cristina Maria Costantino, Achla Gupta, Alice W. Yewdall, Benjamin M. Dale, et al
PLoS One, 2012
—
Agents that activate cannabinoid receptor pathways have been tested as treatments for cachexia, nausea or neuropathic pain in HIV-1/AIDS patients. The cannabinoid receptors (CB(1)R and CB(2)R) and the HIV-1 co-receptors, CCR5 and CXCR4, all signal via Gαi-coupled pathways. We…